Royston P - Search Results

1

Interferon alfa-2a versus combination therapy with interferon alfa-2a, interleukin-2, and fluorouracil in patients with untreated metastatic renal cell carcinoma (MRC RE04/EORTC GU 30012): an open-label randomised trial.

Gore ME, Griffin CL, Hancock B, Patel PM, Pyle L, Aitchison M, James N, Oliver RT, Mardiak J, Hussain T, Sylvester R, Parmar MK, Royston P, Mulders PF. Gore ME, et al. Among authors: royston p. Lancet. 2010 Feb 20;375(9715):641-8. doi: 10.1016/S0140-6736(09)61921-8. Epub 2010 Feb 10. Lancet. 2010. PMID: 20153039 Free PMC article. Clinical Trial.

2

Flexible parametric proportional-hazards and proportional-odds models for censored survival data, with application to prognostic modelling and estimation of treatment effects.

Royston P, Parmar MK. Royston P, et al. Stat Med. 2002 Aug 15;21(15):2175-97. doi: 10.1002/sim.1203. Stat Med. 2002. PMID: 12210632

3

Visualizing length of survival in time-to-event studies: a complement to Kaplan-Meier plots.

Royston P, Parmar MK, Altman DG. Royston P, et al. J Natl Cancer Inst. 2008 Jan 16;100(2):92-7. doi: 10.1093/jnci/djm265. Epub 2008 Jan 8. J Natl Cancer Inst. 2008. PMID: 18182621 Clinical Trial.

4

The use of restricted mean survival time to estimate the treatment effect in randomized clinical trials when the proportional hazards assumption is in doubt.

Royston P, Parmar MK. Royston P, et al. Stat Med. 2011 Aug 30;30(19):2409-21. doi: 10.1002/sim.4274. Epub 2011 May 25. Stat Med. 2011. PMID: 21611958

5

Prognostic factors for renal cell carcinoma.

Furniss D, Harnden P, Ali N, Royston P, Eisen T, Oliver RT, Hancock BW; National Cancer Research Institute Renal Clinical Studies Group. Furniss D, et al. Among authors: royston p. Cancer Treat Rev. 2008 Aug;34(5):407-26. doi: 10.1016/j.ctrv.2007.12.008. Epub 2008 Apr 28. Cancer Treat Rev. 2008. PMID: 18440705 Review.

6

Novel designs for multi-arm clinical trials with survival outcomes with an application in ovarian cancer.

Royston P, Parmar MK, Qian W. Royston P, et al. Stat Med. 2003 Jul 30;22(14):2239-56. doi: 10.1002/sim.1430. Stat Med. 2003. PMID: 12854091

7

External Validation of the 2003 Leibovich Prognostic Score in Patients Randomly Assigned to SORCE, an International Phase III Trial of Adjuvant Sorafenib in Renal Cell Cancer.

Oza B, Eisen T, Frangou E, Stewart GD, Bex A, Ritchie AWS, Kaplan R, Smith B, Davis ID, Stockler MR, Albiges L, Escudier B, Larkin J, Joniau S, Hancock B, Hermann GG, Bellmunt J, Parmar MKB, Royston P, Meade A. Oza B, et al. Among authors: royston p. J Clin Oncol. 2022 Jun 1;40(16):1772-1782. doi: 10.1200/JCO.21.01090. Epub 2022 Feb 25. J Clin Oncol. 2022. PMID: 35213214 Free PMC article. Clinical Trial.

8

Restricted mean survival time: an alternative to the hazard ratio for the design and analysis of randomized trials with a time-to-event outcome.

Royston P, Parmar MK. Royston P, et al. BMC Med Res Methodol. 2013 Dec 7;13:152. doi: 10.1186/1471-2288-13-152. BMC Med Res Methodol. 2013. PMID: 24314264 Free PMC article.

9

Meta-analysis of time-to-event outcomes from randomized trials using restricted mean survival time: application to individual participant data.

Wei Y, Royston P, Tierney JF, Parmar MK. Wei Y, et al. Among authors: royston p. Stat Med. 2015 Sep 20;34(21):2881-98. doi: 10.1002/sim.6556. Epub 2015 Jun 23. Stat Med. 2015. PMID: 26099573 Free PMC article.

10

An approach to trial design and analysis in the era of non-proportional hazards of the treatment effect.

Royston P, Parmar MK. Royston P, et al. Trials. 2014 Aug 7;15:314. doi: 10.1186/1745-6215-15-314. Trials. 2014. PMID: 25098243 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

185 results

Search Page